Condition: Prostate Cancer · Sponsor: AstraZeneca
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Duarte, California, United States | Recruiting |
| Research Site | San Francisco, California, United States | Not Yet Recruiting |
| Research Site | Tampa, Florida, United States | Not Yet Recruiting |
| Research Site | Boston, Massachusetts, United States | Not Yet Recruiting |
| Research Site | St Louis, Missouri, United States | Recruiting |
| Research Site | Myrtle Beach, South Carolina, United States | Recruiting |
| Research Site | Nashville, Tennessee, United States | Recruiting |
| Research Site | Salt Lake City, Utah, United States | Not Yet Recruiting |
| Research Site | Melbourne, Australia | Recruiting |
| Research Site | Calgary, Alberta, Canada | Recruiting |
| Research Site | Vancouver, British Columbia, Canada | Not Yet Recruiting |
| Research Site | Chengdu, China | Not Yet Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07336446